Prophylaxis for venous thromboembolism during asparaginase therapy in patients treated for acute lymphoblastic leukemia

Mandy N. Lauw; Lowiek M. Hubers; Cornelia H. van Ommen; Barbara A. Hutten; Bart J. Biemond; Saskia Middeldorp

doi:10.1002/14651858.CD010049.pub2

Prophylaxis for venous thromboembolism during asparaginase therapy in patients treated for acute lymphoblastic leukemia

Mandy N. Lauw^*, Lowiek M. Hubers, Cornelia H. van Ommen, Barbara A. Hutten, Bart J. Biemond, Saskia Middeldorp

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: Primary objectives of this review are: to investigate and summarize whether thromboprophylactic measures are effective in reducing the incidence of VTE during asparaginase therapy in primary ALL remission induction treatment for pediatric and adult patients; to investigate the impact of thromboprophylaxis used during primary ALL remission induction treatment on overall survival. Secondary objectives of this review are: to investigate and summarize the adverse effects of thromboprophylactic measures during asparaginase therapy in primary ALL remission induction treatment, to address their safety (Loke 2011); to investigate and summarize which thromboprophylactic measure is the most effective in reducing the VTE incidence during asparaginase therapy in primary ALL remission induction treatment; to investigate the impact of thromboprophylaxis used during asparaginase therapy in primary ALL remission induction treatment on ALL treatment outcome, expressed in complete remission rates.

Original language	English
Article number	CD010049
Journal	Cochrane Database of Systematic Reviews
Volume	2016
Issue number	5
DOIs	https://doi.org/10.1002/14651858.CD010049.pub2
Publication status	Published - 31 May 2016
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2016 The Cochrane Collaboration.

Access to Document

10.1002/14651858.CD010049.pub2

Prophylaxis for venous thromboembolism during asparaginase therapy in patients treated for acute lymphoblastic leukemiaFinal published version, 43.2 KBLicence: Article 25fa Dutch Copyright Act

Cite this

@article{07d244e97d1943bc8ea9693c215f7ade,

title = "Prophylaxis for venous thromboembolism during asparaginase therapy in patients treated for acute lymphoblastic leukemia",

abstract = "This is the protocol for a review and there is no abstract. The objectives are as follows: Primary objectives of this review are: to investigate and summarize whether thromboprophylactic measures are effective in reducing the incidence of VTE during asparaginase therapy in primary ALL remission induction treatment for pediatric and adult patients; to investigate the impact of thromboprophylaxis used during primary ALL remission induction treatment on overall survival. Secondary objectives of this review are: to investigate and summarize the adverse effects of thromboprophylactic measures during asparaginase therapy in primary ALL remission induction treatment, to address their safety (Loke 2011); to investigate and summarize which thromboprophylactic measure is the most effective in reducing the VTE incidence during asparaginase therapy in primary ALL remission induction treatment; to investigate the impact of thromboprophylaxis used during asparaginase therapy in primary ALL remission induction treatment on ALL treatment outcome, expressed in complete remission rates.",

author = "Lauw, {Mandy N.} and Hubers, {Lowiek M.} and {van Ommen}, {Cornelia H.} and Hutten, {Barbara A.} and Biemond, {Bart J.} and Saskia Middeldorp",

note = "Publisher Copyright: {\textcopyright} 2016 The Cochrane Collaboration.",

year = "2016",

month = may,

day = "31",

doi = "10.1002/14651858.CD010049.pub2",

language = "English",

volume = "2016",

journal = "Cochrane Database of Systematic Reviews",

issn = "1465-1858",

publisher = "John Wiley & Sons Ltd.",

number = "5",

}

TY - JOUR

T1 - Prophylaxis for venous thromboembolism during asparaginase therapy in patients treated for acute lymphoblastic leukemia

AU - Lauw, Mandy N.

AU - Hubers, Lowiek M.

AU - van Ommen, Cornelia H.

AU - Hutten, Barbara A.

AU - Biemond, Bart J.

AU - Middeldorp, Saskia

PY - 2016/5/31

Y1 - 2016/5/31

N2 - This is the protocol for a review and there is no abstract. The objectives are as follows: Primary objectives of this review are: to investigate and summarize whether thromboprophylactic measures are effective in reducing the incidence of VTE during asparaginase therapy in primary ALL remission induction treatment for pediatric and adult patients; to investigate the impact of thromboprophylaxis used during primary ALL remission induction treatment on overall survival. Secondary objectives of this review are: to investigate and summarize the adverse effects of thromboprophylactic measures during asparaginase therapy in primary ALL remission induction treatment, to address their safety (Loke 2011); to investigate and summarize which thromboprophylactic measure is the most effective in reducing the VTE incidence during asparaginase therapy in primary ALL remission induction treatment; to investigate the impact of thromboprophylaxis used during asparaginase therapy in primary ALL remission induction treatment on ALL treatment outcome, expressed in complete remission rates.

AB - This is the protocol for a review and there is no abstract. The objectives are as follows: Primary objectives of this review are: to investigate and summarize whether thromboprophylactic measures are effective in reducing the incidence of VTE during asparaginase therapy in primary ALL remission induction treatment for pediatric and adult patients; to investigate the impact of thromboprophylaxis used during primary ALL remission induction treatment on overall survival. Secondary objectives of this review are: to investigate and summarize the adverse effects of thromboprophylactic measures during asparaginase therapy in primary ALL remission induction treatment, to address their safety (Loke 2011); to investigate and summarize which thromboprophylactic measure is the most effective in reducing the VTE incidence during asparaginase therapy in primary ALL remission induction treatment; to investigate the impact of thromboprophylaxis used during asparaginase therapy in primary ALL remission induction treatment on ALL treatment outcome, expressed in complete remission rates.

UR - http://www.scopus.com/inward/record.url?scp=84971554453&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD010049.pub2

DO - 10.1002/14651858.CD010049.pub2

M3 - Article

AN - SCOPUS:84971554453

SN - 1465-1858

VL - 2016

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 5

M1 - CD010049

ER -

Prophylaxis for venous thromboembolism during asparaginase therapy in patients treated for acute lymphoblastic leukemia

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this